>

JeanPierre Bizzari - COMPUGEN Director

<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:4em;padding-top: 25px;;'>CO</div>
CGEN -- Israel Stock  

 1,402  1,106  44.10%

  Director
Dr. JeanPierre Bizzari was appointed Director at Compugen Ltd. effective September 5, 2018. He is a worldrenowned oncology expert, member of the Scientific Advisory Board of the French National Cancer Institute and European Organization of Research and Treatment of Cancer and Chairman of the New Drug Advisory Committee. He holds Directorship at a variety of biotech companies
Age: 63  Director Since 2018  Ph.D    
(972) 3 765 8555  www.cgen.com
Bizzari holds a Doctorate of Medicine degree, specializing in oncology, from the University of Nice completed with training at the PitieSalpetriere hospital in Paris, the Ontario Cancer Institute and at The McGill Rosalind and Morris Goodman Cancer Research Centre in Montreal, Canada.

Management Efficiency

The company has accumulated 3.58 M in total debt with debt to equity ratio (D/E) of 9.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. COMPUGEN has Current Ratio of 7.05 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Yaakov DromyARAD LTD
2010
Aric CohenARAD LTD
2017
Amos MalkaDELEK AUTOMOTIVE S
2010
Ephraim AbramsonARAD LTD
2017
Tamar GaliliMEDTECHNICA
2011
Morris BenistyMEDTECHNICA
2019
Shacham MittlerARAD LTD
2010
Dror PazARAD LTD
2014
Asaf BartfeldDELEK AUTOMOTIVE S
1992
Daniel VakninARAD LTD
2017
Irit TobiasDELEK AUTOMOTIVE S
2018
Malka DorDELEK AUTOMOTIVE S
2011
Gabriel LastDELEK AUTOMOTIVE S
2010
Israel TchetchikDELEK AUTOMOTIVE S
2013
Oded TiraARAD LTD
2007
Reuven LevinMEDTECHNICA
N/A
Shmuel LeshemARAD LTD
2019
Guy BenDrorARAD LTD
2009
Ishay TzelinkerARAD LTD
2012
Serhin VekslerARAD LTD
2011
Tal YaronEldarMEDTECHNICA
2012

Company Summary

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company was incorporated in 1993 and is headquartered in Holon, Israel. COMPUGEN operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 61 people.COMPUGEN (CGEN) is traded on Tel Aviv Stock Exchange in Israel and employs 61 people.

COMPUGEN Leadership Team

Joshua Shemer, Independent External DirectorView
Michal Preminger, DirectorView
Paul Sekhri, Chairman of the BoardView
Dov Hershberg, DirectorView
Martin Gerstel, Chairman of the BoardView
Arie Ovadia, Independent External DirectorView
Zurit Levine, Vice President - Research and DiscoveryView
Eran Perry, DirectorView
Ari Krashin, Chief Financial OfficerView
Sanford Zweifach, DirectorView
Gilead Halevy, DirectorView
Anat CohenDayag, President, Chief Executive Officer, DirectorView
Ruth Arnon, Independent DirectorView
Kinneret Savitsky, DirectorView
Henry Adewoye, Chief Medical OfficerView
Yair Aharonowitz, Independent External DirectorView
JeanPierre Bizzari, DirectorView
John Hunter, VP of Antibody RandD and Site Head of Compugen USA IncView

Stock Performance Indicators

Current Sentiment - CGEN

COMPUGEN Investor Sentiment

Macroaxis portfolio users are unresponsive in their opinion about investing in COMPUGEN. What is your opinion about investing in COMPUGEN? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

COMPUGEN Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for COMPUGEN and CIM COMMERICAL TRU. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to Trending Equities. Please also try Aroon Oscillator module to analyze current equity momentum using aroon oscillator and other momentum ratios.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page